Novartis AG (NVS) Given Consensus Rating of “Hold” by Analysts
Shares of Novartis AG (NYSE:NVS) have been given a consensus recommendation of “Hold” by the eighteen brokerages that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $83.19.
A number of analysts have recently issued reports on NVS shares. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 price objective on the stock in a report on Tuesday, September 19th. Cowen set a $90.00 target price on shares of Novartis and gave the stock a “hold” rating in a report on Wednesday, August 9th. BidaskClub upgraded shares of Novartis from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Leerink Swann boosted their target price on shares of Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis in a report on Tuesday, October 24th.
Several institutional investors have recently made changes to their positions in NVS. City Holding Co. boosted its holdings in shares of Novartis by 4.6% during the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after buying an additional 54 shares in the last quarter. WFG Advisors LP grew its position in shares of Novartis by 38.1% during the second quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after purchasing an additional 337 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in shares of Novartis during the third quarter worth about $106,000. Cable Hill Partners LLC grew its position in shares of Novartis by 588.8% during the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after purchasing an additional 1,107 shares in the last quarter. Finally, Harding Loevner LP purchased a new stake in shares of Novartis during the second quarter worth about $146,000. 10.87% of the stock is owned by institutional investors.
Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.04. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The firm had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. During the same quarter in the previous year, the firm posted $1.23 earnings per share. The business’s revenue was up 2.4% on a year-over-year basis. research analysts forecast that Novartis will post 4.75 EPS for the current year.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.